Publications
Publications
- February 1992 (Revised April 1995)
- HBS Case Collection
Pfizer: Global Protection of Intellectual Property
By: Lynn S. Paine and Michael Santoro
Abstract
Top officials at Pfizer are assessing their strategy for improving protection of Pfizer's patents around the world. The outcome of the Uruguay Round of the GATT negotiations is uncertain, and it is not clear whether an acceptable intellectual property protection agreement will emerge. The case describes how Pfizer helped transform intellectual property from a lawyer's specialty to an international trade issue of concern around the world through close cooperation with the U.S. government, leadership in forming a tripartite coalition among U.S., Japanese, and European industry, and mobilization of the Pfizer organization. Shows how far a company may go to protect its intellectual property in a world where the concept of intellectual property is not universally recognized or accepted. May also be used to discuss the effectiveness and legitimacy of Pfizer's strategy, the conflicts between industrialized country and developing country perspectives on international trade and national sovereignty, and the question of appropriate norms of intellectual property protection.
Keywords
Patents; Trade; Policy; Government And Politics; Business Strategy; Agreements And Arrangements; Alliances; Cross-cultural And Cross-border Issues; Pharmaceutical Industry; United States; Japan; Europe
Citation
Paine, Lynn S., and Michael Santoro. "Pfizer: Global Protection of Intellectual Property." Harvard Business School Case 392-073, February 1992. (Revised April 1995.)
About The Author
